Aura Biosciences Stock (NASDAQ:AURA)

Forecast Ownership Financials Chart

Previous Close

$6.12

52W Range

$4.73 - $9.54

50D Avg

$7.26

200D Avg

$6.25

Market Cap

$398.68M

Avg Vol (3M)

$504.39K

Beta

0.39

Div Yield

AURA Company Profile

Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

106

IPO Date

Oct 29, 2021

Website

AURA Performance

AURA Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	-	$-84.99M	$-60.30M
Net Income	$-86.92M	$-76.41M	$-57.23M
EBITDA	-	$-83.70M	$-59.12M
Basic EPS	$-1.75	$-1.93	$-1.91
Diluted EPS	$-1.75	$-1.93	$-1.91

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
LBRX	LB Pharmaceuticals Inc Common Stock
QSI	Quantum-Si incorporated
DSGN	Design Therapeutics, Inc.
ALT	Altimmune, Inc.
ANNX	Annexon, Inc.
ENGN	enGene Holdings Inc.
SLDB	Solid Biosciences Inc.
RCKT	Rocket Pharmaceuticals, Inc.
DBVT	DBV Technologies S.A.
KRRO	Korro Bio, Inc.